InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-28.2%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Moxham Christopher, Directeur Scientifique. Officer active across 1 company, notably Fulcrum Therapeutics, Inc.. Cumulatively, 2 reports have been published. History available since 10 August 2021. The latest transaction was filed on 10 August 2021 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations2 total
20,714 shares@ US$7.8450.0% of flowCommon StockSEC:0000899243-21-032755
20,714 shares@ US$7.840.031% mcap50.0% of flowCommon StockSEC:0000899243-21-032755:0
2 of 2 declarations
About Moxham Christopher
Christopher Moxham is the Chief Scientific Officer at Fulcrum Therapeutics, Inc. He is responsible for scientific direction and innovation within the company. His role is essential in developing new treatments and therapeutic solutions.
